Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy
The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Proximal spinal muscular atrophy (SMA) is a common neuromuscular disorder causing infant death in half of all patients. Homozygous absence of the survival motor neuron gene (SMN1) is the primary cause of SMA, while SMA severity is mainly determined by the number of SMN2 copies. One SMN2 copy produces only about 10% of full-length protein identical to SMN1, whereas the majority of SMN2 transcripts is aberrantly spliced due to a silent mutation within an exonic splicing enhancer in exon 7. However, correct splicing can be restored by over-expression of the SR-like splicing factor Htra2-beta 1. We show that in fibroblast cultures derived from SMA patients treated with therapeutic doses (0.5-500 microM) of valproic acid (VPA), the level of full-length SMN2 mRNA/protein increased 2- to 4-fold. Importantly, this up-regulation of SMN could be most likely attributed to increased levels of Htra2-beta 1 which facilitates the correct splicing of SMN2 RNA as well as to an SMN gene transcription activation. Especially at low VPA concentrations, the restored SMN level depended on the number of SMN2 copies. Moreover, VPA was able to increase SMN protein levels through transcription activation in organotypic hippocampal brain slices from rats. Finally, VPA also increased the expression of further SR proteins, which may have important implications for other disorders affected by alternative splicing. Since VPA is a drug highly successfully used in long-term epilepsy therapy, our findings open the exciting perspective for a first causal therapy of an inherited disease by elevating the SMN2 transcription level and restoring its correct splicing.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Identification and characterization of a spinal muscular atrophy-determining gene
Lefebvre, S., Bürglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90460-3 · Cited by 3,990
A simple method for organotypic cultures of nervous tissue
Stoppini, L., Buchs, P.-A., & Muller, D. (1991) · Journal of Neuroscience Methods · doi:10.1016/0165-0270(91)90128-m · Cited by 3,089
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887
Lorson, C. L., Hahnen, E., Androphy, E. J., & Wirth, B. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.11.6307 · Cited by 1,532
Feldkötter, M., Schwarzer, V., Wirth, R., Wienker, T. F., & Wirth, B. (2002) · The American Journal of Human Genetics · doi:10.1086/338627 · Cited by 1,004
Hockly, E., Richon, V. M., Woodman, B., Smith, D. L., Zhou, X., Rosa, E., Sathasivam, K., Ghazi-Noori, S., Mahal, A., Lowden, P. A. S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437870100 · Cited by 845
What's Up and Down with Histone Deacetylation and Transcription?
Pazin, M. J., & Kadonaga, J. T. (1997) · Cell · doi:10.1016/s0092-8674(00)80211-1 · Cited by 821
Cartegni, L., & Krainer, A. R. (2002) · Nature Genetics · doi:10.1038/ng854 · Cited by 730
Wirth, B. (2000) · Human Mutation · doi:10.1002/(sici)1098-1004(200003)15:3<228::aid-humu3>3.0.co;2-9 · Cited by 667
International SMA Consortium Meeting (26–28 June 1992, Bonn, Germany)
Munsat, T. L., & Davies, K. E. (1992) · Neuromuscular Disorders · doi:10.1016/s0960-8966(06)80015-5 · Cited by 666
Cited by
Items 301–388 of 388
Баранов, В. С., Kiselev, A., Vakharlovsky, V. G., Железнякова, Г. Ю., Komantzev, V. N., Malisheva, O. V., Glotov, A. S., Иващенко, Т. Э., & Baranov, A. N. (2008) · Russian Journal of Genetics · doi:10.1134/s1022795408100049 · Cited by 6
Mohseni, R., Ashrafi, M. R., Ai, J., Nikougoftar, M., Mohammadi, M., Akbari, M. G., Shoae‐Hassani, A., & Hamidieh, A. A. (2018) · Journal of Molecular Neuroscience · doi:10.1007/s12031-018-1232-x · Cited by 6
Of SMN in mice and men: a therapeutic opportunity
Swoboda, K. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci58752 · Cited by 7
Drug discovery for spinal muscular atrophy
Wirth, B., Rießland, M., & Hahnen, E. (2007) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2.4.437 · Cited by 6
Large‐scale Detection of Genetic Variation: The Key to Personalized Medicine
Geistlinger, J., & Ahnert, P. (2005) · doi:10.1002/9783527620982.ch3 · Cited by 6
Wooley, J. R., Crowder, M. E., Pyles, N. J., & Sumner, C. J. (2017) · Wiley eBooks · doi:10.1002/9781118661895.ch16 · Cited by 6
Jarrige, M., Polvèche, H., Carteron, A., Janczarski, S., Peschanski, M., Auboeuf, D., & Martinat, C. (2021) · iScience · doi:10.1016/j.isci.2021.102767 · Cited by 5
Spinal Muscular Atrophy Therapeutics Development
Sunshine, S., Jarecki, J., MacKenzie, A., & Chen, K. S. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803685-3.00016-1 · Cited by 6
Kim, S., Lee, Y., Kim, S., Lee, S. J., Heo, P. K., Kim, S., Kwon, Y. J., & Lee, K. W. (2018) · Bulletin of the Korean Chemical Society · doi:10.1002/bkcs.11366 · Cited by 6
Erden, D. D., Topaloğlu, H., & Erdem‐Yurter, H. (2008) · Advances in Therapy · doi:10.1007/s12325-008-0030-1 · Cited by 5
Sangiuolo, F. C., Filareto, A., Spitalieri, P., Scaldaferri, M. L., Mango, R., Bruscia, E. M., Citro, G., Brunetti, E., Felici, M. D., & Novelli, G. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.ft-84 · Cited by 5
Sel, E. K., Gkrinia, E. M. M., Roncato, R., Vitezić, D., Јаnkovic, S., & Belančić, A. (2025) · Journal of International Medical Research · doi:10.1177/03000605251397777 · Cited by 5
Pruss, R. M. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.586692 · Cited by 4
Small Molecule Approaches to Upregulate SMN Expression From the SMN2 Locus
Cherry, J. J., Calder, A. N., Hodgetts, K. J., & Androphy, E. J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803685-3.00017-3 · Cited by 5
Genetic Function Approximation and Bayesian Models for the Discovery of Future HDAC8 Inhibitors
Thangapandian, S., John, S., & Keun Woo, L. (2011) · Interdisciplinary Bio Central · doi:10.4051/ibc.2011.3.4.0015 · Cited by 3
Spinal muscular atrophy – a revisit of the diagnosis and treatment modalities
Srivastava, G., & Srivastava, P. (2019) · International Journal of Neuroscience · doi:10.1080/00207454.2019.1635128 · Cited by 4
Current Trends in the Diagnosis, Screening and Treatment of Spinal Muscular Atrophy
Maretina, M. A., Kiselev, A., Ilina, A. V., Egorova, A., Glotov, A. S., Bespalova, O. N., Баранов, В. С., & Kogan, I. Y. (2022) · Annals of the Russian academy of medical sciences · doi:10.15690/vramn1768 · Cited by 4
Review on Spinal Muscular Atrophy
Devade, O. A., Londhe, R. D., & Meshram, N. M. (2022) · Research Journal of Pharmacology and Pharmacodynamics · doi:10.52711/2321-5836.2022.00042 · Cited by 3
Cintado, M. Á., González, G., Cárcel, L., & la Casa, L. G. D. (2023) · PLoS ONE · doi:10.1371/journal.pone.0279511 · Cited by 4
Drug Discovery Approaches for Rare Neuromuscular Diseases
Wynne, G. M., & Russell, A. J. (2014) · Royal Society of Chemistry eBooks · doi:10.1039/9781782624202-00257 · Cited by 3
Taylor, J. P., & Kolb, S. J. (2005) · Neurological disease and therapy · doi:10.1201/9780849358364.ch11 · Cited by 3
Spinal Muscular Atrophy During Human Development: Where Are the Early Pathogenic Findings?
Tizzano, E. F. (2009) · Advances in experimental medicine and biology · doi:10.1007/978-90-481-2813-6_15 · Cited by 3
Fenichel, G. M. (2009) · Elsevier eBooks · doi:10.1016/b978-1-4160-6185-4.00006-x · Cited by 3
Akgün, G., & Bashirov, R. (2024) · Applied Sciences · doi:10.3390/app142210696 · Cited by 2
Epigenetische Pathomechanismen der Epileptogenese
Blümcke, I., Kobow, K., & Becker, A. J. (2011) · Clinical Epileptology · doi:10.1007/s10309-011-0171-0 · Cited by 2
Current and emerging treatment options for spinal muscular atrophy
Farooq, F., & MacKenzie, A. (2015) · Degenerative Neurological and Neuromuscular Disease · doi:10.2147/dnnd.s48420 · Cited by 2
Genetically confirmed spinal muscular atrophy type 3 with epilepsy in a Malay patient, a case report
Naing, L., Sutomo, R., & Nishio, H. (2003) · Cited by 2
AVANCES EN EL DIAGNÓSTICO Y MANEJO DE LAS ENFERMEDADES NEUROMUSCULARES
Claudia Castiglioni, T., Eliana Rodillo, B., & Cecilia Hervias, R. (2008) · Revista Médica Clínica Las Condes · Cited by 2
Duranay, R., Bashirov, R., & Şeytanoğlu, A. (2017) · Procedia Computer Science · doi:10.1016/j.procs.2017.11.236 · Cited by 2
Deguise, M., & Kothary, R. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813796-3.00002-x · Cited by 2
Cell Culture Models of Spinal Muscular Atrophy
Ng, S., & Rubin, L. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803685-3.00013-6 · Cited by 1
Advances in the Potential Role and Mechanism of Fibroblasts in Spinal Muscular Atrophy
Chen, C., Zhang, J., Xue, C., Liu, D., & Li, S. (2025) · Cell Biochemistry and Function · doi:10.1002/cbf.70118 · Cited by 1
Discovery, SAR and Biological Evaluation of Aryl-thiazol-piperidines as SMN Modulators
Xiao, J., Marugán, J., Zheng, W., Titus, S., Southall, N. T., Cherry, J. J., Evans, M. C., Androphy, E. J., & Austin, C. P. (2011) · Cited by 1
RNA Pathologies in Neurological Disorders
Ohno, K., & Masuda, A. (2010) · Advances in neurobiology · doi:10.1007/978-1-4419-7104-3_14 · Cited by 1
Spinal Muscular Atrophy: Current Therapeutic Strategies
Kiselyov, A. S., & Gurney, M. E. (2010) · Topics in medicinal chemistry · doi:10.1007/7355_2010_7 · Cited by 1
Confirmation of the Spinal Motor Neuron Gene 2 (SMN2) Copy Numbers by Real-time PCR
Maamouri-Hicheri, W., Hammer, M. B., Bouhlal, Y., Souilem, S., Nawel, T., Ines, M.-A., Wajdi, B., Khmiri, N., Houda, N., Hentati, F., et al. (2012) · Diagnostic Molecular Pathology · doi:10.1097/pdm.0b013e31824696b6 · Cited by 1
Therapeutic Strategies for the Treatment of Spinal Muscular Atrophy (SMA) Disease
Sangiuolo, F. C., Botta, A., Filareto, A., Spitalieri, P., & Novelli, G. (2006) · Current Genomics · doi:10.2174/138920206778948691 · Cited by 1
Current and investigational treatments for spinal muscular atrophy
Tam, J. K. V., Karyka, E., & Azzouz, M. (2014) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2014.901910 · Cited by 2
Xie, J. (2013) · International Journal of Genomic Medicine · doi:10.4172/2332-0672.1000105 · Cited by 1
Amyotrophic lateral sclerosis: epidemiology, risk factors and treatment
de Jong, S. (2012) · Cited by 1
Stem cells and cancer: A review
Ullah, N., Liaqat, S., Fatima, S., Zehra, F., Anwer, M., & Sadiq, M. (2016) · Asian Pacific Journal of Tropical Disease · doi:10.1016/s2222-1808(15)61057-x · Cited by 1
Ganai, S. A. (2019) · Springer eBooks · doi:10.1007/978-981-13-8019-8_6 · Cited by 1
Induced pluripotent stem cells for modeling of spinal muscular atrophy
Welby, E., & Ebert, A. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85764-2.00010-7 · Cited by 1
Analysis of HPV-16 Late Gene Expression
Orrù, B. (2012) · Arrow - TU Dublin (Technological University Dublin) · doi:10.21427/d7jg68 · Cited by 1
Erden, D. D., Topaloğlu, H., & Erdem‐Yurter, H. (2008) · DergiPark (Istanbul University)
Treatment strategies in amyotrophic lateral sclerosis and its mimics
Piepers, S. (2003) · Utrecht University Repository (Utrecht University)
Pajares, V., & Isabel, A. (2009) · Tesis Doctorals en Xarxa (Consorci de Serveis Universitaris de Catalunya)
Mouse mutants and cell culture models of motoneuron disease
Sendtner, M. (2004) · Drug Discovery Today Disease Models · doi:10.1016/j.ddmod.2004.10.008
Brichta, L. (2006) · Kölner Universitäts PublikationsServer (Universität zu Köln)
Self-citationHauke, J. (2009) · Kölner Universitäts PublikationsServer (Universität zu Köln)
Naturally occurring plant polyphenols as potential therapies for inherited
Fuller, H. R., Emma, L. V. L., & Glenn, E. M. (2013)
Farooq, F. (2012) · uO Research (University of Ottawa) · doi:10.20381/ruor-3135
Lehmann, H. C., Köller, H., & Hartung, H. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9780511995590.052
Baioni, M. T. C., & Ambiel, C. R. (2010)
Advances in neuromuscular disease 2003: the year in review.
Alexianu, M. E., & Gooch, C. L. (2004) · PubMed · doi:10.1097/01.cnd.0000127138.99732.28
Current and potential therapeutics in motor neuron diseases
Wood-Allum, C. A., & Shaw, P. J. (2005) · Cambridge University Press eBooks · doi:10.1017/cbo9780511544873.053
Defining the therapeutic window in spinal muscular atrophy :||time points study
Robbins, K. L. (2013) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/44711
Glascock, J. (2013) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/44658
Saito, T., Harahap, I. S. K., Fujimura, H., Saito, K., & Nishio, H. (2017) · Journal of Neurological Disorders · doi:10.4172/2329-6895.1000367
Powis, R. A. (2016) · Edinburgh Research Archive (University of Edinburgh)
MECHANISM OF ACTION OF HISTONE DEACETYLASE INHIBITORS ON SURVIVAL MOTOR NEURON 2 PROMOTER
Grimme, A. L. (2018) · Library, Museums and Press - UDSpace (University of Delaware)
The Effects of Rufinamide on in Vitro Spinal Muscular Atrophy Model
Ando, S., Sato, A., Funato, M., Ohuchi, K., Inagaki, S., Nakamura, S., Shimazawa, M., Kaneko, H., & Hara, H. (2019) · Pharmacology & Pharmacy · doi:10.4236/pp.2019.104014
Biomimetic Materials: Polymeric Substrates for Axonal Regeneration
Farrell, K. W., & Kothapalli, C. R. (2015) · Taylor & Francis eBooks · doi:10.1081/e-ebpp-120050595
Swalley, S. E., & Cheung, A. K. (2020) · Royal Society of Chemistry eBooks · doi:10.1039/9781839160721-00140
Disease-specific neurorehabilitation systems
Selzer, M. E., Clarke, S., Cohen, L. G., Kwakkel, G., & Miller, R. H. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9780511995590.044
Lee, J., Horak, C. E., Khanna, C., Meng, Z., Yu, L., Veenstra, T. D., & Steeg, P. S. (2023) · doi:10.1158/0008-5472.c.6497348
Barraza, S. J., & Woll, M. G. (2024) · Methods and principles in medicinal chemistry · doi:10.1002/9783527840458.ch7
Stem cell therapy in neurodegenerative disorders
Hefnawy, M. T., Shaheen, N., Elsamman, K., Husain, M. A., Mostafa, N., Khalil, M., Amro, Y., & Meshref, M. M. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-15702-8.00032-4
Dual Role of Transformer 2 Beta as Both a Developmental Necessity and a Disease Modulator
Swarup, E., & Qiu, H. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26188805
MEDICAMENTOUS THERAPY OF THE DUCHENNE MUSCULAR DYSTROPHY AND THE SPINAL MUSCULAR ATROPHY
Sokolova, M. G., Никишина, О. А., Maretina, M. A., Kiselev, A., Лобзин, С. В., & Zuev, A. A. (2017) · Medical academic journal · doi:10.17816/maj17124-33
Different Neuroprotective Activities of Proanthocyanidin-Enriched Fractions of Lotus Species
Ceccarini, M. R., Mazzarella, N., Visone, S., Santonicola, P., Camera, A., Cieri, F., Rocca, F. L., Matino, I., Zampi, G., Valeri, M. C., et al. (2025) · ACS Omega · doi:10.1021/acsomega.5c06714
Epigenetic Therapies in Neurological Diseases
Huang, H., Philpot, B. D., & Jiang, Y. (2013) · Epigenetics and human health · doi:10.1007/978-3-642-36827-1_8
Variabilité phénotypique et épissage : combinaison d'analyses in vitro et in silico du gène CFTR
Aissat, A. (2012) · theses.fr (ABES) · doi:10.70675/5b1bcfaez5daaz41c0z8af2zbd48e8dfc67b
Dodré, M. (2014) · theses.fr (ABES) · doi:10.70675/b97d6973z95aaz4364z8030z3b86fc1d910d
Target-Based Discovery of Drug Combinations for Spinal Muscular Atrophy
Bashirov, R. (2026) · Advances in experimental medicine and biology · doi:10.1007/978-3-032-20041-9_3
Therapeutic strategies for spinal muscular atrophy: the history and future perspective
Liu, J., Liu, Y., Yuan, A., & Ning, K. (2026) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2026.1833269
Rini, P. G., Doreswamy, Y., & Laxmi, T. R. (2026) · Annals of Neurosciences · doi:10.1177/09727531261491531
BindingDB (2012) · UC San Diego · doi:10.7270/q22f7nvf
BindingDB (2024) · UC San Diego · doi:10.7270/q20v8j1b
BindingDB Entry 3587: DcpS as a therapeutic target for spinal muscular atrophy.
BindingDB (2011) · UC San Diego · doi:10.7270/q2z036hn
Class I Lysine Deacetylases Facilitate Glucocorticoid Receptor-Mediated Transcriptional Activation
Kadiyala, V. (2013) · UA Campus Repository (The University of Arizona)
Wiedemann, F. R. (2005) · Elsevier eBooks · doi:10.1016/b978-343723390-6.50054-1
Metadata
- Authors
- Brichta, L.
- Affiliations
- University of Bonn (DE)
- Corresponding author
- Brichta, L.
- ORCID
- Brichta, L.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2003-08-05
- Volume
- 12
- Issue
- 19
- Pages
- 2481-2489
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2151318390
- Cited by
- 382
- References
- 41
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 7 · 2023: 5 · 2022: 4 · 2021: 6 · 2020: 6 · 2019: 12 · 2018: 8 · 2017: 11 · 2016: 14 · 2015: 15 · 2014: 15 · 2013: 31 · 2012: 18
- FWCI
- 12.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Human Molecular Genetics (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Genetics (clinical) › Neurogenetic and Muscular Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
- Keywords
- valproic acid, spinal muscular atrophy, SMN2, SMN1, SR proteins, alternative splicing, exonic splicing enhancers, drug repurposing, inherited neuromuscular disease
- MeSH terms
- Animals, Antibodies, Monoclonal, Cells, Cultured, Dose-Response Relationship, Drug, Exons, Fibroblasts, Gene Expression Regulation, Hippocampus, Humans, Muscular Atrophy, Spinal, Nerve Tissue Proteins, Organ Culture Techniques, RNA Splicing, RNA, Messenger, Time Factors, Transcription, Genetic, Valproic Acid, Blotting, Western, Genetic Therapy, Rats, Wistar, Gene Deletion, GABA Agents, Reverse Transcriptase Polymerase Chain Reaction, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.